Patients with peripheral artery disease (PAD), coronary heart disease, and diabetes mellitus have been shown conclusively to experience a 25% reduction in the rate of cardiovascular death, myocardial infarction, stroke and revascularization procedures by treatment with 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase inhibitors. Despite these findings, patients with PAD are frequently undertreated with respect to HMG-CoA reductase inhibitors, compared to patients with CHD. In addition, HMG-CoA reductase inhibitors produce numerous pleiotrophic effects that may reduce the incidence of restenosis after revascularization procedures.
|Original language||English (US)|
|Number of pages||5|
|Journal||Vascular Disease Management|
|State||Published - Jul 2006|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine